Particularly, JAK2/3 are suitable targets for the treatment of hematologic tumors and myeloproliferative neoplasms [8,9]; however, the discovery of JAK2/3 inhibitors remains a challenge. This evidence concerns the gene JAK2 and hematopoietic and lymphoid cell neoplasm.